Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil

Cancer Research

Volumn 68, Issue 17, 2008, Pages 7035-7041

  Zhao, Hong Ye ^a   Ooyama, Akio ^b   Yamamoto, Masatatsu ^a   Ikeda, Ryuji ^a   Haraguchi, Misako ^a   Tabata, Sho ^a   Furukawa, Tatsuhiko ^a   Che, Xiao Fang ^a   Zhang, Shaoxuan ^a   Oka, Toshinori ^b   Fukushima, Masakazu ^b   Nakagawa, Masayuki ^a   Ono, Mayumi ^c   Kuwano, Michihiko ^d   Akiyama, Shin Ichi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; EARLY GROWTH RESPONSE FACTOR 1; FLUOROURACIL; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA; THROMBOSPONDIN 1; ANTINEOPLASTIC ANTIMETABOLITE; EGR1 PROTEIN, HUMAN; MESSENGER RNA; PRIMER DNA;

ARTICLE; BINDING SITE; CANCER CELL; COLON CARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; BIOSYNTHESIS; CHROMATIN IMMUNOPRECIPITATION; COLON TUMOR; CONFOCAL MICROSCOPY; DOSE RESPONSE; ENZYME ACTIVATION; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY GROWTH RESPONSE PROTEIN 1; ENZYME ACTIVATION; FLUOROURACIL; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THROMBOSPONDIN 1;

EID: 52049124464     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6496     Document Type: Article

References (34)

1. Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anticancer Drugs 1996;7:137-49.
2. Tanaka F. UFT (Tegafur and Uracil) as postoperative adjuvant chemotherapy for solid tumors (Carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. Surg Today 2007;37:923-43.
3. Ho DH, Pazdur R, Covington WP, et al. Comparison of 5-fluorouracil pharma-cokinetics in patients receiving continuous 5-fluorouraci infusion and oral uracil plus 1-5(2-tertahydrofuryl)-5-fluorouracil. Clin Cancer Res 1998;4:2085-8.
4. Munoz R, Man S, Shaked Y, et al. Advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006;66:3386-91.
5. Ooyama A, Oka T, Zhao HY, et al. Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett 2008;267:26-36.
6. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil. Oncologist 2002;7:288-323.
7. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006;1765:178-88.
8. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implicatio ns for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101-11.
9. Munoz R, Shaked Y, Bertolini F, et al. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005;14:466-79.
10. Okamoto M, Ono M, Uchiumi T, et al. Up-regulation of thrombospondin-1gene by epidermal growth factor and transforming growth factor β in human cancer cells-transcriptional activation and messenger RNA stabilization. Biochim Biophys Acta 2002;1574:24-34.
11. Zhao HY, Ooyama A, Yamamoto M, et al. Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells. Cancer Lett. In press. 2008.
12. Quinones A, Dobberstein KU, Rainov NG. The egr-1 gene is induced by DNA-damaging agents and nongenotoxic drugs in both normal and neoplastic human cells. Life Sci 2003;2:297-5.
13. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A 1999;96:3775-80.
14. Hazzalin CA, Cuenda A, Cano E, et al. Effects of the inhibition of p38/RK MAP kinase on induction of five fos and jun genes by diverse stimuli. Oncogene 1997;15:2321-31.
15. Wen XF, Yang G, Mao W, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006;25:6986-96.
16. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 2003;100:12917-22.
17. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003;22:63-71.
18. Donoviel DB, Framson P, Eldridge CF, et al. Structural analysis and expression of the human thrombospondin gene promoter. J Biol Chem 1988;263:18590-93.
19. Laherty CD, Gierman TM, Dixit VM. Characterization of the promoter region of the human thrombospondin gene. DNA sequences within the first intron increase transcription. J Biol Chem 1989;264:11222-7.
20. Shingu T, Bornstein P. Overlapping Egr-1 and Sp1 sites function in the regulation of transcription of the mouse thrombospondin 1 gene. J Biol Chem 1994;269:32551-7.
21. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003;9:1026-32.
22. Yan SF, Fujita T, Lu J, et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000;6:1355-61.
23. Silverman ES, Collins T. Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol 1999;154:665-70.
24. Pignatelli M, Luna-Medina R, Perez-Rendon A, Santos A, Perez-Castillo A. The transcription factor early growth response factor-1 (EGR-1) promotes apoptosis of neuroblastoma cells. Biochem J 2003;373:739-46.
25. Virolle T, Adamson ED, Baron V, et al. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 2001;3:1124-8.
26. Huang RP, Darland T, Okamura D, Mercola D, Adamson ED. Suppression of v-sis-dependent transformation by the transcription factor, Egr-1. Oncogene 1994;9:1367-77.
27. Lucerna M, Pomyje J, Mechtcheriakova D, et al. Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res 2006;66:6708-13.
28. Makin G, Dive C. Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy. Breast Cancer Res 2001;3:150-3.
29. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, p38 protein kinases. Science 2002;298:1911-2.
30. Rouse J, Cohen P, Trigon S, et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994;78:1027-37.
31. Rolli M, Kotlyarov A, Sakamoto KM, et al. Stress-induced stimulation of early growth response gene-1 by p38/stress-activated protein kinase 2 is mediated by a cAMP-responsive promoter element in a MAPKAP kinase 2-independent manner. J Biol Chem 1999;274:9559-64.
32. Arrigo AP, Simon S, Gibert B, et al. Hsp27 (HspB1) and αB-crystallin (HspB5) as therapeutic targets. FEBS Lett 2007;581:3665-74.
33. Oesterreich S, Schunck H, Benndorf R, Bielka H. Cisplatin induces the small heat shock protein hsp25 and thermotolerance in Ehrlich ascites tumor cells. Biochem Biophys Res Commun 1991;180:243-8.
34. Kato K, Ito H, Inaguma Y, et al. Synthesis and accumulation of αB crystallin in C6 glioma cells is induced by agents that promote the disassembly of microtubules. J Biol Chem 1996;271:26989-94.